WallStreetZenWallStreetZen

NASDAQ: SPRY
Ars Pharmaceuticals Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for SPRY

Based on 3 analysts offering 12 month price targets for Ars Pharmaceuticals Inc

Min Forecast
$27.00+81.45%
Avg Forecast
$28.33+90.41%
Max Forecast
$30.00+101.61%

Should I buy or sell SPRY stock?

Based on 3 analysts offering ratings for Ars Pharmaceuticals Inc.

Strong Buy
Strong Buy
1 analysts 33.33%
Buy
2 analysts 66.67%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although SPRY's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates SPRY as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their SPRY stock forecasts and price targets.

SPRY stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-03-07
lockedlocked$00.00+00.00%2025-01-14
lockedlocked$00.00+00.00%2025-01-13

1 of 1

Forecast return on equity

Is SPRY forecast to generate an efficient return?

Company
56.68%
Industry
147.71%
Market
81.76%
SPRY's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is SPRY forecast to generate an efficient return on assets?

Company
41.45%
Industry
35.52%
SPRY is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

SPRY earnings per share forecast

What is SPRY's earnings per share in the next 3 years based on estimates from 5 analysts?

Avg 1 year Forecast
-$1.28-1,702.5%
Avg 2 year Forecast
-$0.47-690.63%
Avg 3 year Forecast
$0.30+275%
SPRY's earnings are forecast to... subscribe to Premium to read more.
Forecast High Earnings Growth Forecast

SPRY revenue forecast

What is SPRY's revenue in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
$89.3M+0.13%
Avg 2 year Forecast
$232.2M+160.41%
Avg 3 year Forecast
$357.8M+301.34%
SPRY's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

SPRY earnings growth forecast

How is SPRY forecast to perform vs Biotechnology companies and vs the US market?

Company
56.74%
Industry
13.37%
Market
18.2%
SPRY's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Industry Forecast
SPRY's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Market Forecast
SPRY's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Savings Rate Forecast

SPRY revenue growth forecast

How is SPRY forecast to perform vs Biotechnology companies and vs the US market?

Company
59.45%
Industry
65.42%
Market
10.4%
SPRY's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
SPRY's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

SPRY vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
SPRY$14.88$28.33+90.41%Strong Buy
IRON$42.17$98.83+134.40%Strong Buy
KNSA$20.21$37.25+84.31%Strong Buy
IDYA$17.08$48.83+185.91%Buy
BEAM$17.00$48.43+184.88%Strong Buy
View Top Biotech Stocks

Ars Pharmaceuticals Stock Forecast FAQ

Is Ars Pharmaceuticals Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 3 Wall Street analysts covering (NASDAQ: SPRY) stock is to Strong Buy SPRY stock.

Out of 3 analysts, 1 (33.33%) are recommending SPRY as a Strong Buy, 2 (66.67%) are recommending SPRY as a Buy, 0 (0%) are recommending SPRY as a Hold, 0 (0%) are recommending SPRY as a Sell, and 0 (0%) are recommending SPRY as a Strong Sell.

If you're new to stock investing, here's how to buy Ars Pharmaceuticals stock.

What is SPRY's earnings growth forecast for 2025-2027?

(NASDAQ: SPRY) Ars Pharmaceuticals's forecast annual earnings growth rate of 56.74% is forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 13.37%, and it is also forecast to beat the US market's average forecast earnings growth rate of 18.2%.

Ars Pharmaceuticals's earnings in 2025 is $7,998,000.On average, 5 Wall Street analysts forecast SPRY's earnings for 2025 to be -$125,789,589, with the lowest SPRY earnings forecast at -$145,217,310, and the highest SPRY earnings forecast at -$92,232,616. On average, 4 Wall Street analysts forecast SPRY's earnings for 2026 to be -$46,361,607, with the lowest SPRY earnings forecast at -$119,706,161, and the highest SPRY earnings forecast at $0.

In 2027, SPRY is forecast to generate $29,435,941 in earnings, with the lowest earnings forecast at -$20,605,159 and the highest earnings forecast at $78,495,843.

What is SPRY's revenue growth forecast for 2025-2027?

(NASDAQ: SPRY) Ars Pharmaceuticals's forecast annual revenue growth rate of 59.45% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 65.42%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.4%.

Ars Pharmaceuticals's revenue in 2025 is $89,149,000.On average, 4 Wall Street analysts forecast SPRY's revenue for 2025 to be $8,758,860,544, with the lowest SPRY revenue forecast at $5,412,288,389, and the highest SPRY revenue forecast at $12,650,586,330. On average, 4 Wall Street analysts forecast SPRY's revenue for 2026 to be $22,778,708,738, with the lowest SPRY revenue forecast at $14,622,794,390, and the highest SPRY revenue forecast at $29,785,247,702.

In 2027, SPRY is forecast to generate $35,106,579,033 in revenue, with the lowest revenue forecast at $30,460,311,954 and the highest revenue forecast at $37,515,125,861.

What is SPRY's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: SPRY) forecast ROA is 41.45%, which is higher than the forecast US Biotechnology industry average of 35.52%.

What is SPRY's Price Target?

According to 3 Wall Street analysts that have issued a 1 year SPRY price target, the average SPRY price target is $28.33, with the highest SPRY stock price forecast at $30.00 and the lowest SPRY stock price forecast at $27.00.

On average, Wall Street analysts predict that Ars Pharmaceuticals's share price could reach $28.33 by Mar 7, 2026. The average Ars Pharmaceuticals stock price prediction forecasts a potential upside of 90.41% from the current SPRY share price of $14.88.

What is SPRY's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: SPRY) Ars Pharmaceuticals's current Earnings Per Share (EPS) is $0.08. On average, analysts forecast that SPRY's EPS will be -$1.28 for 2025, with the lowest EPS forecast at -$1.48, and the highest EPS forecast at -$0.94. On average, analysts forecast that SPRY's EPS will be -$0.47 for 2026, with the lowest EPS forecast at -$1.22, and the highest EPS forecast at $0.00. In 2027, SPRY's EPS is forecast to hit $0.30 (min: -$0.21, max: $0.80).

What is SPRY's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: SPRY) forecast ROE is 56.68%, which is considered strong.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.